This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Stemsynergy Therapeutics, Inc.. Active years: 2026.
Company Filing History:
Years Active: 2026
Title: Thomas Doundoulakis: Innovator in MYC Inhibitors
Introduction
Thomas Doundoulakis is a notable inventor based in Nashville, TN (US). He has made significant contributions to the field of biotechnology, particularly in the development of MYC inhibitors. His work is crucial in advancing therapeutic options for various diseases.
Latest Patents
Doundoulakis holds a patent titled "MYC INHIBITORS AND USES THEREOF." This patent represents his innovative approach to targeting MYC, a gene that plays a critical role in cell growth and proliferation. His research aims to provide new avenues for treatment in oncology and other related fields. He has 1 patent to his name.
Career Highlights
Currently, Thomas Doundoulakis is associated with Stemsynergy Therapeutics, Inc. This company focuses on developing cutting-edge therapies that leverage the latest scientific discoveries. His role at Stemsynergy Therapeutics allows him to apply his expertise in a collaborative environment, driving forward the mission of the company.
Collaborations
Doundoulakis has worked alongside talented colleagues, including Dennis Liang Fei and Samir Saleh. Their combined efforts contribute to the innovative projects at Stemsynergy Therapeutics, fostering a culture of creativity and scientific inquiry.
Conclusion
Thomas Doundoulakis is a prominent figure in the field of biotechnology, with a focus on MYC inhibitors. His contributions through patents and collaboration with esteemed colleagues highlight his commitment to advancing medical science. His work continues to inspire future innovations in therapeutic development.